

# Aikou Okamoto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4827278/publications.pdf>

Version: 2024-02-01

56  
papers

1,776  
citations

471509

17  
h-index

289244

40  
g-index

59  
all docs

59  
docs citations

59  
times ranked

2851  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between fetal sex and pregnancy outcomes among women with twin pregnancies: a multicenter cross-sectional study. <i>Archives of Gynecology and Obstetrics</i> , 2023, 307, 1397-1405.	1.7	3
2	Impact of COVID-19 on gynecologic cancer treatment in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO). <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	9
3	Altered cervicovaginal microbiota in premenopausal ovarian cancer patients. <i>Gene</i> , 2022, 811, 146083.	2.2	8
4	Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial. <i>Gynecologic Oncology</i> , 2022, 164, 278-287.	1.4	6
5	Analysis of postoperative adjuvant therapy in 102 patients with gastric-type mucinous carcinoma of the uterine cervix: A multi-institutional study. <i>European Journal of Surgical Oncology</i> , 2022, , .	1.0	4
6	Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma. <i>Cancer Science</i> , 2022, , .	3.9	2
7	PHOSPHATE exporter XPR1/SLC53A1 is required for the tumorigenicity of epithelial ovarian cancer. <i>Cancer Science</i> , 2022, 113, 2034-2043.	3.9	7
8	CRISPR/Cas9 Screening for Identification of Genes Required for the Growth of Ovarian Clear Cell Carcinoma Cells. <i>Current Issues in Molecular Biology</i> , 2022, 44, 1587-1596.	2.4	0
9	Impact of COVID-19 on cervical cancer screening in Japan: A survey of population-based screening in urban Japan by the Japan Society of Gynecologic Oncology. <i>Journal of Obstetrics and Gynaecology Research</i> , 2022, 48, 757-765.	1.3	7
10	Efficacy of edoxaban for the treatment of gynecological cancer-associated venous thromboembolism: analysis of Japanese real-world data. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	2
11	Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification. <i>Clinical Cancer Research</i> , 2022, 28, 3546-3556.	7.0	5
12	Clear cell carcinoma of the ovary: a clinical and molecular perspective. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 605-616.	2.5	79
13	Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e16.	2.2	8
14	Safety assessment of the prophylactic use of silicone gel sheets (Lady Care <sup>®</sup> ) for the prevention of hypertrophic scars following caesarean section. <i>Journal of Obstetrics and Gynaecology</i> , 2021, 41, 380-384.	0.9	0
15	Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1769.	3.7	21
16	Initiatives and achievements of the Japanese Society of Obstetrics and Gynecology, Obstetrics and Gynecology MIRAI Committee 2020. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 1973-1977.	1.3	4
17	Clinical Availability of Tumour Biopsy Using Diagnostic Laparoscopy for Advanced Ovarian Cancer. <i>In Vivo</i> , 2021, 35, 3325-3331.	1.3	6
18	A case of laparoscopically treated broad ligament ectopic pregnancy followed by spontaneous gestation. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, , .	1.3	0

#	ARTICLE	IF	CITATIONS
19	Association between hospital treatment volume and survival of women with gynecologic malignancy in Japan: a JSOG tumor registry-based data extraction study. <i>Journal of Gynecologic Oncology</i> , 2021, 33, .	2.2	4
20	Differences in pregnancy complications and outcomes by fetal gender among Japanese women: a multicenter cross-sectional study. <i>Scientific Reports</i> , 2020, 10, 18810.	3.3	13
21	Direct Assessment of Single-Cell DNA Using Crudely Purified Live Cells: A Proof of Concept for Noninvasive Prenatal Definitive Diagnosis. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 132-140.	2.8	7
22	Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2020, 25, 425-431.	2.2	25
23	Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. <i>European Journal of Cancer</i> , 2020, 130, 114-125.	2.8	134
24	Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e86.	2.2	22
25	The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e94.	2.2	4
26	Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma. <i>Gynecologic Oncology</i> , 2019, 155, 489-498.	1.4	21
27	Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 155, 39-50.	1.4	16
28	Analysis of gastric-type mucinous carcinoma of the uterine cervix – An aggressive tumor with a poor prognosis: A multi-institutional study. <i>Gynecologic Oncology</i> , 2019, 153, 13-19.	1.4	89
29	The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1). <i>Gynecologic Oncology</i> , 2019, 153, 312-319.	1.4	17
30	Association of Radical Hysterectomy Surgical Volume and Survival for Early-Stage Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2019, 133, 1086-1098.	2.4	77
31	Molecular genetic analysis reveals atypical confined placental mosaicism with a small supernumerary marker chromosome derived from chromosome 18: A clinical report of discordant results from three prenatal tests. <i>European Journal of Medical Genetics</i> , 2019, 62, 103533.	1.3	3
32	Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. <i>Quality of Life Research</i> , 2018, 27, 59-74.	3.1	40
33	Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). <i>Gynecologic Oncology</i> , 2018, 148, 36-41.	1.4	26
34	Somatic copy number alterations have prognostic impact in patients with ovarian clear cell carcinoma. <i>Oncology Reports</i> , 2018, 40, 309-318.	2.6	16
35	Clinical associations of Trousseau's syndrome associated with cerebral infarction and ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e67.	2.2	17
36	Retrospective analysis of sites of recurrence in stage I epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e37.	2.2	19

#	ARTICLE	IF	CITATIONS
37	PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma. <i>Oncotarget</i> , 2018, 9, 15266-15274.	1.8	16
38	Hyperchromatic crowded cell groups in BD SurePath <sup>TM</sup> method. <i>The Journal of the Japanese Society of Clinical Cytology</i> , 2018, 57, 13-18.	0.0	0
39	Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. <i>Nature Genetics</i> , 2017, 49, 856-865.	21.4	220
40	Higuchi's transverse incision and a modification of this method for minimally invasive surgery. <i>Gynecology and Minimally Invasive Therapy</i> , 2017, 6, 66-68.	0.9	2
41	Feasibility of reduced port surgery applying Higuchi's transverse incision. <i>Gynecology and Minimally Invasive Therapy</i> , 2017, 6, 12-16.	0.9	1
42	Update on rare epithelial ovarian cancers; based on the Rare Ovarian Tumors Young Investigator Conference. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e54.	2.2	20
43	Comparison of the positive rate of HSIL or worse and percentage of unsatisfactory specimens between BD SurePath <sup>TM</sup> and conventional methods. <i>The Journal of the Japanese Society of Clinical Cytology</i> , 2017, 56, 225-231.	0.0	0
44	High risk HPV rate of detection and the genotyping study used remainder specimen of BD SurePath <sup>TM</sup> method. <i>The Journal of the Japanese Society of Clinical Cytology</i> , 2017, 56, 276-282.	0.0	0
45	Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer. <i>International Journal of Clinical Oncology</i> , 2016, 21, 435-446.	2.2	57
46	Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2881-2887.	1.6	114
47	Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes. <i>American Journal of Pathology</i> , 2016, 186, 1103-1113.	3.8	71
48	Detection of a Missing Surgical Device during Laparoscopic Gynecologic Surgery: Case report. <i>Japanese Journal of Gynecologic and Obstetric Endoscopy</i> , 2015, 30, 450-454.	0.0	0
49	Somatic Copy Number Alterations Associated with Japanese or Endometriosis in Ovarian Clear Cell Adenocarcinoma. <i>PLoS ONE</i> , 2015, 10, e0116977.	2.5	28
50	Cytological variations and typical diagnostic features of endocervical adenocarcinoma <i>in situ</i> : A retrospective study of 74 cases. <i>CytoJournal</i> , 2015, 12, 8.	1.7	11
51	Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Ovary. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S20-S25.	2.5	116
52	Randomized phase III trial of paclitaxel/carboplatin (PC) versus cisplatin/irinotecan (CPT-P) as first-line chemotherapy in patients with clear cell carcinoma (CCC) of the ovary: A Japanese Gynecologic Oncology Group (JGOG)/GCIG study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5507-5507.	1.6	12
53	Presence and Future of Photodynamic Therapy(PDT) in Recurrent Cervical Cancer. <i>Nippon Laser Igakkaishi</i> , 2012, 33, 136-140.	0.0	0
54	Current Status and Future Perspectives of the Photodynamic Therapy for Early Stage Cancer and Dysplasia of the Uterine Cervix. <i>Nippon Laser Igakkaishi</i> , 2012, 33, 117-121.	0.0	0

#	ARTICLE	IF	CITATIONS
55	Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells. <i>Clinical Cancer Research</i> , 2005, 11, 6030-6039.	7.0	361
56	Allelic imbalance in chromosome band 18q21 and SMAD4 mutations in ovarian cancers. , 1999, 24, 264-271.		25